Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy

Journal of Neurology

Volumn 260, Issue 11, 2013, Pages 2892-2893

  Le Saché, Nolwenn ^a   Afanetti, Mickael ^a   Deiva, Kumaran ^a   Chevret, Laurent ^a   Tissières, Pierre ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; IMMUNOGLOBULIN; MEROPENEM; METHYLPREDNISOLONE; RITUXIMAB; TOXIC SHOCK SYNDROME TOXIN 1;

ANTIBIOTIC THERAPY; ANTIGEN PRESENTING CELL; CASE REPORT; CHILD; ENCEPHALITIS; EPILEPTIC STATE; HEART ARREST; HUMAN; LETTER; MALE; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESUSCITATION; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; TOXIC SHOCK SYNDROME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; CHILD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84889571876     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7107-8     Document Type: Letter

References (10)

1. Irani SR, Vincent A (2011) NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep 11:298-304
2. Lappin E, Ferguson AJ (2009) Gram-positive toxic shock syndromes. Lancet Infect Dis 9:281-290
3. Stevens DL, Ma Y, Salmi DB et al (2007) Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195:202-211
4. Darenberg J, Ihendyane N, Sjolin J et al (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37:333-340
5. Kaul R, McGeer A, Norrby-Teglund A et al (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28:800-807
6. Schlievert PM (2001) Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 108:107-110
7. UK Department of Health (2008) Clinical guidelines for immunoglobulin use (2nd edn.)
8. Looney RJ, Srinivasan R, Calabrese LH (2008) The effects of Rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 58:5-14
9. Kavcic M, Fisher BT, Seif AE et al (2013) Leveraging administrative data to monitor rituximab use in 2,875 patients at 42 freestanding children's hospitals across the United States. J Pediatr 162:1252-1258
10. Van Vollenhoven RF, Ezery P, Bingham CO et al (2010) Long-term safety of patients receiving Rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558-567